Clinical trials: Specific Immunotherapy
Cat Allergy, Cat Hypersensitivity
A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy
The goal of this study is to identify changes in cells that are related to the treatment with Cat-PAD (ToleroMune Cat).
- Trial name
- NCT02311413
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Malignant Melanoma
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying vaccine therapy to see how well it works in treating patients with…
- Trial name
- NCT00128583
- Testing
- polyvalent melanoma vaccine
- Where
- 11 sites in United States, Australia
- Sponsor
- CancerVax Corporation
Hodgkins Lymphoma
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
The investigators intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP…
- Trial name
- NCT01636388
- Testing
- allogeneic donor derived LMP specific cytotoxic T-lymphocyte
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- New York Medical College
Cytomegalovirus Infection, Adenovirus Infection
Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation
Invasive infections with CMV and Adenovirus, not responding to virostatic treatment are treated with virusspecific donor derived or autologous virusspecific T-cells.
- Trial name
- VISIT (NCT02702427)
- Testing
- virus-specific T-Cells
- Where
- Austria
- Sponsor
- St. Anna Kinderkrebsforschung
Solid Tumors, Advanced Cancer
Personalized Neoantigen Peptide Vaccines for Solid Tumors
This clinical trial is studying the safety and efficacy of a personalized cancer vaccine called a neoantigen peptide vaccine in patients with solid tumors.
- Conditions
- Solid Tumors, Advanced Cancer, Recurrent Cancer, Neoantigen-Specific Immunotherapy
- Trial name
- NCT07002203
- Testing
- Personalized Neoantigen Peptide Vaccine
- Where
- Thailand
- Volunteers
- 10 people
- Sponsor
- Seqker Biosciences, Inc.
Cancer
Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells
The primary objectives are to evaluate the safety and efficacy of infusion of autologous tumor associated antigen-specific engineered immune effector cells (EIE).
- Trial name
- NCT03535246
- Testing
- Engineered Immune Cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Allogeneic Stem Cell Transplantation
CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease
The purpose of this study is to determine the safety and feasibility of CMV specific, T cell adoptive immunotherapy in patients who have undergone allogeneic stem cell transplantation for malignant disease.
- Trial name
- CMV-BMT (NCT00611637)
- Testing
- CMV pp65 Specific T Cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Kim Lyerly
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
This phase I trial studies the highest possible dose of memory enriched T cells that can be given following standard stem cell transplant before unmanageable side effects are seen in patients with B-cell non-Hodgkin lymphoma that…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma
- Trial name
- NCT02051257
- Testing
- Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- City of Hope Medical Center
Allergic Asthma
Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma
The purpose of this study is to determine whether a short course of subcutaneous immunotherapy is efficacious in mite induced asthma. The efficacy is based on reduction in control medication.
- Trial name
- NCT00492076
- Testing
- Pangramin Plus D. pteronyssinus 100%
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- ALK-Abelló A/S
Ovarian Neoplasm
p53 Vaccine for Ovarian Cancer
This study will examine whether vaccination with a p53 peptide can boost an immune response to ovarian cancer and what the side effects are of the vaccine.
- Trial name
- NCT00001827
- Testing
- aldesleukin, incomplete Freund's adjuvant, p53 peptide vaccine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Type 1 Diabetes Mellitus
Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
The purpose of this study is to determine whether treatment with multiple injections of GAD-Alum will preserve the body's own (endogenous) insulin production in patients who have been recently diagnosed with type 1 diabetes…
- Trial name
- TN08 (NCT00529399)
- Testing
- GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide
- Where
- 15 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Melanoma (Skin)
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, may be used to prepare the body for other treatments, such as cellular adoptive immunotherapy.
- Trial name
- NCT00324623
- Testing
- Melan-A VLP vaccine, IMP321 adjuvant, adoptive immunotherapy, therapeutic autologous lymphocytes
- Where
- Switzerland
- Volunteers
- 8 people
- Sponsor
- Prof. Serge Leyvraz
HER2/Neu Positive, HLA-A2 Positive Cells Present
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
This phase I/II trial studies the side effects of vaccine therapy and to see how well it works in treating patients with stage IV major histocompatibility complex, class I, A2 antigen (HLA-A2) and human epidermal growth factor…
- Conditions
- HER2/Neu Positive, HLA-A2 Positive Cells Present, Stage IV Breast Cancer, Stage IV Ovarian Cancer
- Trial name
- NCT00194714
- Testing
- HER-2/neu Peptide Vaccine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Recurrent Melanoma, Stage IV Melanoma
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
RATIONALE: Laboratory-treated T cells may be able to kill tumor cells when they are put back into the body. Aldesleukin and cyclophosphamide may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00553306
- Testing
- therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fred Hutchinson Cancer Center